By David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT Business Update Phase 3 Plan for MDNA55 Program On October 15, 2020, Medicenna Therapeutics Corp. (NASDAQ:MDNA) provided an update for the MDNA55 program following an ‘End-of-Phase 2’ meeting with the U.S. FDA. The FDA has guided for the company to proceed with a Phase […]
Continue reading
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Cycle 3 Data Shows Continued Efficacy for SGX301 in Phase 3 CTCL Trial On October 22, 2020, Soligenix, Inc. (NASDAQ:SNGX) announced data from Cycle 3 of the Phase 3 FLASH clinical trial of SGX301 in cutaneous T cell lymphoma (CTCL) shows continued […]
Continue readingBy David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Manufacturing Agreement with Catalent On October 22, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced an agreement with Catalent, Inc. (CTLT) for the manufacture of NurOwn®, which is currently being evaluated in a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis […]
Continue reading
By Steven Ralston, CFA NYSE:XIN READ THE FULL XIN RESEARCH REPORT Xinyuan Real Estate (NYSE:XIN) develops and sells real estate properties, primarily large-scale, high quality, multi-family residential projects in strategically selected high growth cities (Tier 1 and Tier 2) in China. In China, the company acquires land for development, primarily through public auctions of government […]
Continue readingBy Beth Senko, CFA OTC:UCASU READ THE FULL UCASU RESEARCH REPORT The pandemic continues to throw uncertainty into the economy and markets, making it difficult, if not impossible, for many to look past 2020, or even next week. Recent studies suggest that in the past three months, between six and eight million Americans have fallen […]
Continue reading
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Topline Data from Phase 3 ALS Trial Before End of November 2020 BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS) (NCT03280056). A total of 200 patients were randomized […]
Continue reading
